



Food and Drug Administration  
Rockville, MD 20857

# FILE COPY

January 5, 2005

Robert W. Pollock  
Vice President  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to declare that the drug product, Risperidone Orally Disintegrating Tablets, 0.25 mg, is suitable for consideration in an abbreviated new drug application was received by this office on 01/05/2005. It was assigned docket number 2005P-0007/CP 1 and it was filed on 01/05/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2005P-0007

ACK 1